The expression of serum oncostatin M in sepsis patients and its role in early recognition of sepsis_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

FAN Liuru ¹ , ZHANG Lizhong ² , LI Jinlan ¹ ,  LI Xiaoyan ¹

1. Department of Respiratory and Critical Care Medicine, Third Hostipal of Shanxi Medical University, Shanxi Bethune Hostipal, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P. R. China;
2. Clinical Laboratory, Third Hostipal of Shanxi Medical University, Shanxi Bethune Hostipal, Tongji Shanxi Hospital,Taiyuan, Shanxi 030032, P. R. China;

Corresponding author：

LI Xiaoyan, Email: 2415960869@qq.com

Keywords：

Sepsis; oncostatin M; early diagnosis

DOI：

10.7507/1671-6205.202205049

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression of oncostatin M (OSM) in patients with sepsis and its role in early recognition of sepsis. Methods Thirty-four patients with sepsis admitted in Shanxi Bethune Hospital fromJune 3, 2021 to January 18, 2022 were selected as a sepsis group, 15 patients with community acquired pneumonia (CAP) as a case control group, and 16 adults who underwent physical examination in the same period were selected as a healthy control group. The patients in the sepsis group were followed up for 28 days and divided into a survival group and a death group. The serum OSM level and its correlation with clinical indexes (white blood cell, neutrophil, lymphocyte, sequential organ failure assessment score and acute physiology and chronic health evaluation Ⅱ) were analyzed, and the diagnostic value of OSM expression level in the early identification of sepsis was analyzed. Results Compared with the case control group and the healthy control group, the expression level of OSM in the sepsis group was significantly higher [(502.07±209.93)pg/mL vs. (368.22±65.95)pg/mL and (382.09±73.04)pg/mL, P<0.05]. However, the high expression of OSM had no significant correlation with white blood cell, neutrophil, lymphocyte or disease severity score (P>0.05), and there was no significant difference in serum OSM level between the sepsis survival group and the death group. Compared with white blood cell count, the high expression of OSM has certain diagnostic value in the early identification of sepsis. The area under the receiver operator characteristic curve of OSM in predicting sepsis was 0.794 (95% confidence interval 0.666 - 0.922, P<0.05), with the sensitivity of 79.4% and the specificity of 73.3%. Conclusion The expression of OSM in patients with sepsis is significantly increased, and the high expression of OSM has a certain diagnostic value in the early identification of sepsis.

Citation： FAN Liuru, ZHANG Lizhong, LI Jinlan, LI Xiaoyan. The expression of serum oncostatin M in sepsis patients and its role in early recognition of sepsis. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(6): 412-416. doi: 10.7507/1671-6205.202205049 Copy

1.	Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA, 2016, 315(8): 775-787.
2.	Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet, 2020, 395(10219): 200-211.
3.	Xie JF, Wang HL, Kang Y, et al. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey. Crit Care Med, 2020, 48(3): e209-e218.
4.	Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med, 2021, 49(11): e1063-e1143.
5.	Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci, 2013, 50(1): 23-36.
6.	Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev, 2015, 26(5): 545-558.
7.	Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018, 18(12): 773-789.
8.	Richards CD. The enigmatic cytokine oncostatin M and roles in disease. ISRN Inflamm, 2013, 2013: 512103.
9.	West NR, Owens B, Hegazy AN. The oncostatin M-stromal cell axis in health and disease. Scand J Immunol, 2018, 88(3): e12694.
10.	Hermans D, Houben E, Baeten P, et al. Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity. Acta Neuropathol, 2022, 144(2): 259-281.
11.	Botelho F, Dubey A, Ayaub EA, et al. IL-33 mediates lung inflammation by the IL-6-Type cytokine Oncostatin M. Mediators Inflamm, 2020, 2020: 4087315.
12.	Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, 315(8): 801-810.
13.	中华医学会呼吸病学分会; 瞿介明, 曹彬. 中国成人社区获得性肺炎诊断和治疗指南(2016年版). 中华结核和呼吸杂志, 2016, 39(4): 253-279.
14.	van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity, 2021, 54(11): 2450-2464.
15.	Taga T. gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem, 1996, 67(1): 1-10.
16.	Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol, 2003, 149: 39-52.
17.	Brown TJ, Rowe JM, Liu JW, et al. Regulation of IL-6 expression by oncostatin M. J Immunol, 1991, 147(7): 2175-2180.
18.	Brown TJ, Liu JW, Brashem-Stein C, et al. Regulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor expression by oncostatin M. Blood, 1993, 82(1): 33-37.
19.	Richards CD, Brown TJ, Shoyab M, et al. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol, 1992, 148(6): 1731-1736.
20.	Young PY, Mueller TF, Sis B, et al. Oncostatin M plays a critical role in survival after acute intestinal ischemia: reperfusion injury. Surg Infect (Larchmt), 2020, 21(9): 799-806.
21.	Traber KE, Hilliard KL, Allen E, et al. Induction of STAT3-dependent CXCL5 expression and neutrophil recruitment by oncostatin-M during pneumonia. Am J Respir Cell Mol Biol, 2015, 53(4): 479-488.
22.	Gong Y, Yan XX, Sun XM, et al. Oncostatin M is a prognostic biomarker and inflammatory mediator for sepsis. J Infect Dis, 2020, 221(12): 1989-1998.
23.	Lin GL, McGinley JP, Drysdale SB, et al. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol, 2018, 9: 2147.
24.	Li H, Liu L, Zhang DY, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 2020, 395(10235): 1517-1520.
25.	李彭, 谢丽华, 孙圣华, 等. 社区获得性肺炎合并脓毒症患者临床特征及死亡危险因素分析. 中国呼吸与危重监护杂志, 2022, 21(4): 260-268.

1. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA, 2016, 315(8): 775-787.
2. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet, 2020, 395(10219): 200-211.
3. Xie JF, Wang HL, Kang Y, et al. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey. Crit Care Med, 2020, 48(3): e209-e218.
4. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med, 2021, 49(11): e1063-e1143.
5. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci, 2013, 50(1): 23-36.
6. Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev, 2015, 26(5): 545-558.
7. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018, 18(12): 773-789.
8. Richards CD. The enigmatic cytokine oncostatin M and roles in disease. ISRN Inflamm, 2013, 2013: 512103.
9. West NR, Owens B, Hegazy AN. The oncostatin M-stromal cell axis in health and disease. Scand J Immunol, 2018, 88(3): e12694.
10. Hermans D, Houben E, Baeten P, et al. Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity. Acta Neuropathol, 2022, 144(2): 259-281.
11. Botelho F, Dubey A, Ayaub EA, et al. IL-33 mediates lung inflammation by the IL-6-Type cytokine Oncostatin M. Mediators Inflamm, 2020, 2020: 4087315.
12. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, 315(8): 801-810.
13. 中华医学会呼吸病学分会; 瞿介明, 曹彬. 中国成人社区获得性肺炎诊断和治疗指南(2016年版). 中华结核和呼吸杂志, 2016, 39(4): 253-279.
14. van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity, 2021, 54(11): 2450-2464.
15. Taga T. gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem, 1996, 67(1): 1-10.
16. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol, 2003, 149: 39-52.
17. Brown TJ, Rowe JM, Liu JW, et al. Regulation of IL-6 expression by oncostatin M. J Immunol, 1991, 147(7): 2175-2180.
18. Brown TJ, Liu JW, Brashem-Stein C, et al. Regulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor expression by oncostatin M. Blood, 1993, 82(1): 33-37.
19. Richards CD, Brown TJ, Shoyab M, et al. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol, 1992, 148(6): 1731-1736.
20. Young PY, Mueller TF, Sis B, et al. Oncostatin M plays a critical role in survival after acute intestinal ischemia: reperfusion injury. Surg Infect (Larchmt), 2020, 21(9): 799-806.
21. Traber KE, Hilliard KL, Allen E, et al. Induction of STAT3-dependent CXCL5 expression and neutrophil recruitment by oncostatin-M during pneumonia. Am J Respir Cell Mol Biol, 2015, 53(4): 479-488.
22. Gong Y, Yan XX, Sun XM, et al. Oncostatin M is a prognostic biomarker and inflammatory mediator for sepsis. J Infect Dis, 2020, 221(12): 1989-1998.
23. Lin GL, McGinley JP, Drysdale SB, et al. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol, 2018, 9: 2147.
24. Li H, Liu L, Zhang DY, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 2020, 395(10235): 1517-1520.
25. 李彭, 谢丽华, 孙圣华, 等. 社区获得性肺炎合并脓毒症患者临床特征及死亡危险因素分析. 中国呼吸与危重监护杂志, 2022, 21(4): 260-268.

Chinese Journal of Respiratory and Critical Care Medicine

The expression of serum oncostatin M in sepsis patients and its role in early recognition of sepsis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content